UK MHRA chief urges caution over drug trial data release
This article was originally published in SRA
Executive Summary
Publishing full clinical study reports may not be the best way to increase transparency of clinical trial data, mainly because of the time and cost involved in redacting personal data, according to Professor Sir Kent Woods, outgoing head of the UK regulatory agency, the MHRA1.